This study demonstrates the superiority of [68Ga]-DOTATATE PET/CT compared with all other currently used functional imaging modalities in patients with SDHB mutation-related pheochromocytomas/paragangliomas, including the currently recommended functional imaging method of choice [18F]-FDG PET/CT. These results might initiate a change in future guidelines to shift towards the use of [68Ga]-DOTA-peptides. The results of this study imply that these patients, who often suffer from metastatic disease and otherwise have limited treatment options, may benefit from peptide receptor radionuclide therapy or even treatment with so-called “cold” synthetic somatostatin analogs, which could become new important treatment options for SDHB-related pheochromocytomas and paragangliomas.

The Trop-2 antigen is a new cancer therapeutic target. Starodub and colleagues studied it as a target for an antibody-drug conjugate by conjugating an anti-Trop-2 antibody with SN-38, the active metabolite of a well-known anticancer chemotherapeutic, camptothecin (irinotecan), in 25 heavily pretreated patients with...

You do not currently have access to this content.